Lindsey Roeker, MD, Discusses Which Data From ASH 2021 Have the Biggest Potential to Impact Care

Lindsey Roeker, MD, spoke about data presented at ASH 2021 and what she thought to be most interesting.

At the 2021 American Society of Hematology Annual Meeting, CancerNetwork® spoke with Lindsey Roeker, MD, a hematologic oncologist at Memorial Sloan Kettering Cancer Center in New York, about which presentations she found to be most insightful and thought would have the biggest impact on the standard of care in the leukemia space.

Transcript:

We’ve been able to see updates on a couple of important new drugs [such as] pirtobrutinib, the noncovalent BTK [Bruton tyrosine kinase] inhibitor that was formerly LOXO-305.1 We saw an update in the data with a focus on the patients who had previously been exposed to BTK inhibitors; that drug is obviously incredibly effective. We also saw an update on the Merck noncovalent BTK inhibitor and got a look at that drug because it had been a while since we’ve received an update. CLL13 [NCT02950051] was another study that was a randomization to chemoimmunotherapy versus venetoclax [Venclexta]–containing regimens, [such as] venetoclax with rituximab [Rituxan], venetoclax with obinutuzumab [Gazyva], or venetoclax with obinutuzumab and ibrutinib [Imbruvica].2 That was the first look at the results from that study, so we gained some insights there as well.

References

1. Mato An, Pagel J, Coombs C, et al. Pirobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study. Presented at the 2021 American Society of Hematology Annual Meeting. December 11-14, 2021. Abstract 391. https://bit.ly/3H4rQ7a

2. Eichhorst B, Niemann C, Kater A, et al. A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: First co-primary endpoint analysis of the international intergroup GAIA (CLL13) trial. Presented at the 2021 American Society of Hematology Annual Conference. December 11-14, 2021. Abstract 71. https://bit.ly/3ej0HRx